134
staff
Alex Schueler
Alex Schueler is a Senior Director, Strategic Markets, Business and Program Development at the Mi
lken Institute. In 2017, she launched the Institute’s office in New York.
+ Read More
staff
Emily Baxi, PhD
Emily Baxi, PhD, is a director at the Milken Institute Center for Strategic Philanthropy.
staff
Anita Totten
Anita Totten is an associate at the Milken Institute, Public Health, providing project and resear
ch support for the Center’s prevention and mental health strategic pillars of work.
+ Read More
staff
Micah Rabin
Micah Rabin is a research intern with the Research Department at the Milken Institute. She suppor
ts the department’s research portfolio in international finance.
+ Read More
staff
Sarah Sandler
Sarah Sandler is the executive director of business and program development at the Milken Institu
te and oversees fundraising strategies across Institute events and programs.
+ Read More
person
Susan Guthrie
staff
Holly Freishtat
Holly Freishtat is the senior director of Feeding Change at the Milken Institute.
report
Learning from COVID-19: Reimagining Public-Private Partnerships in Public Health
The Milken Institute Center for Public Health leveraged our network of thought leaders to maximize
learnings from the COVID-19 pandemic, focused on examining the private sector’s role and responsibility in supp
+ Read More
report
Global Opportunity Index 2022: White Paper
The Global Opportunity Index assesses countries' attractiveness to international investors using a
combination of economic, financial, institutional, and regulatory factors.
+ Read More
report
Global Opportunity Index 2022: Focus on Emerging Southeast Asia
This report uses the 2022 Global Opportunity Index (GOI) and its various categories to examine the
attractiveness of emerging Southeast Asia as a foreign investment destination—especially when compared to other emerging markets and developing economies
+ Read More
report
Strengthening the Biomedical Innovation Ecosystem: A Scorecard for System Assessment
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a
simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the
+ Read More
report
Cell and Gene Therapies: Looking Ahead to 2022
Cell and gene therapies are a new category of medicines transforming how we treat and potentially c
ure disease. Both cell and gene therapies seek to modify genetic material to fight disease.
+ Read More